1. Synthesis and Biological Evaluation of Pyrazolo[3,4-b]pyridin-4-ones as a New Class of Topoisomerase II Inhibitors.
- Author
-
Tabrizi MA, Baraldi PG, Baraldi S, Prencipe F, Preti D, Saponaro G, Romagnoli R, Gessi S, Merighi S, Stefanelli A, Fazzi D, Borea PA, Maia RC, Romeiro NC, Fraga CA, and Barreiro EJ
- Subjects
- Antigens, Neoplasm chemistry, Antigens, Neoplasm metabolism, Antineoplastic Agents pharmacology, Cell Line, Tumor, Cell Survival drug effects, DNA antagonists & inhibitors, DNA chemistry, DNA Topoisomerases, Type II chemistry, DNA Topoisomerases, Type II metabolism, DNA-Binding Proteins chemistry, DNA-Binding Proteins metabolism, Etoposide pharmacology, Humans, Molecular Docking Simulation, Pyrazoles pharmacology, Pyridones pharmacology, Structure-Activity Relationship, Topoisomerase II Inhibitors pharmacology, Antineoplastic Agents chemical synthesis, DNA-Binding Proteins antagonists & inhibitors, Pyrazoles chemical synthesis, Pyridones chemical synthesis, Topoisomerase II Inhibitors chemical synthesis
- Abstract
A series of 1,3,6-triphenylpyrazolo[3,4-b]pyridin-4-one derivatives was designed, synthesized and evaluated for cytotoxic activity in A375 human melanoma and human erythroleukemia (HEL) cells. The new pyrazolopyridones displayed comparable activities to the antitumor compound etoposide. The inhibitory effect of compounds 17, 18, 27 and 32 against topoisomerase II-mediated cleavage activities was measured finding good correlation with the results obtained from MTS assay. Docking studies into bacterial topoisomerase II (DNA Gyrase), topoisomerase IIα and topoisomerase IIβ binding sites in the DNA binding interface were performed.
- Published
- 2015
- Full Text
- View/download PDF